Crinetics Pharmaceuticals Corporate Presentation 2023 | GPCR Endocrine Disorders

Crinetics Pharmaceuticals is developing GPCR-targeted oral small molecules for endocrine disorders and endocrine-related tumors, with lead candidate paltusotine in Phase 3 trials for acromegaly. The company combines a proprietary GPCR drug discovery platform with global endocrinology clinical capabilities and aims to become a fully-integrated endocrine company with multiple late-stage programs.